These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 36878564)
41. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031 [TBL] [Abstract][Full Text] [Related]
42. The changing view of high-grade serous ovarian cancer. Berns EM; Bowtell DD Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197 [TBL] [Abstract][Full Text] [Related]
55. Molecular characterization of 103 ovarian serous and mucinous tumors. Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228 [TBL] [Abstract][Full Text] [Related]
56. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090 [TBL] [Abstract][Full Text] [Related]
57. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
58. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218 [TBL] [Abstract][Full Text] [Related]
59. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500 [TBL] [Abstract][Full Text] [Related]
60. Advances in precision therapy of low-grade serous ovarian cancer: A review. Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]